CClinicalTrials.gg
Sign In
Not yet recruitingNCT07807449Updated Sep 8, 2026

Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older

A Phase 1 interventional study of Recombinant RSV Vaccine (CHO Cell) and Recombinant RSV Vaccine (CHO Cell) in Respiratory Syncytial Virus (RSV), sponsored by Yikang Biotech (Suzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Yikang Biotech (Suzhou) Co., Ltd. · Phase 1, Interventional, and Prevention

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Read the detailed description

This is a single-center, randomized, blinded, placebo-controlled trial. A total of 128 trial participants aged 18 years and older will be enrolled: 64 trial participants aged 18-59 years and 64 trial participants aged 60 years and older. Each age stratum will be divided into four cohorts, for a total of eight cohorts: low-dose antigen cohorts, high-dose antigen cohorts , adjuvant-only cohorts, and low-dose antigen + adjuvant cohorts in the 18-59-year and 60-years-and-older strata.

Eligible trial participants in each cohort will be randomized 3:1 on Day 0 to receive one dose of investigational vaccine (low-dose antigen, high-dose antigen, adjuvant, or low-dose antigen + adjuvant) or placebo. Enrollment will proceed in the order of adults (18-59 years) to older adults (60 years and older), low dose to high dose, and antigen to adjuvant to antigen + adjuvant.

To ensure the safety of the study population, the first four trial participants enrolled in each cohort will be designated as sentinel trial participants and randomized 3:1 to investigational vaccine or placebo.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)

Keywords

  • RSV vaccine
  • Acute Respiratory Infection
  • Lower Respiratory Track Disease
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Adults aged 18 years and older who reside in the local area and can provide legal proof of identity; sex is not restricted;
  2. Trial participants understand the informed consent form and the vaccine to be administered, voluntarily agree to participate and sign the informed consent form, and are able to use a thermometer and ruler and complete the diary card and contact card as required. If a participant is unable to sign the informed consent form independently because of limited literacy, the informed consent process and signature may be completed with the assistance of an impartial witness;
  3. Able to communicate effectively with the investigator and understand and comply with all trial requirements;
  4. Women of childbearing potential (see Appendix 2 for the definition) must have used effective contraception for 2 weeks before enrollment, have a negative urine pregnancy test before investigational vaccine administration (women not of childbearing potential are exempt), and voluntarily agree to continue using at least one effective contraceptive method for 6 months after vaccination. Effective contraception includes oral contraceptives, injectable or implantable contraception, long-acting local contraceptives, hormone patches, intrauterine devices (IUDs), sterilization, abstinence, male condoms, diaphragms, cervical caps, etc. Male trial participants must agree to use effective contraception with female partners of reproductive potential from the screening visit until 6 months after immunization.

Exclusion criteria

Exclusion Criteria:

Trial participants meeting any of the following exclusion criteria may not be enrolled:

  1. Abnormal pre-vaccination laboratory tests (complete blood count, blood biochemistry, coagulation function, C-reactive protein, or urinalysis) or 12-lead electrocardiogram findings that, based on medical history and clinical presentation, render the person unsuitable for vaccination in the investigator's judgment;
  2. Abnormal skin at the vaccination sites on both arms at the vaccination visit (e.g., inflammation, induration, erythema/swelling, or extensive scars);
  3. Hypertension not controlled by medication, or pre-enrollment systolic blood pressure of at least 160 mmHg and/or diastolic blood pressure of at least 100 mmHg;
  4. Axillary temperature of at least 37.1 degrees C on the day of vaccination; fever, acute illness, or an acute exacerbation of chronic disease within the preceding 3 days; or use of antipyretic/analgesic or anti-allergy medications within the preceding 3 days;
  5. Communicable period of any infectious disease, acute infection, or acute phase of chronic infection (e.g., active untreated tuberculosis) (by interview);
  6. Laboratory-confirmed RSV infection within the previous 12 months, or previous receipt of, or planned receipt of, any marketed or investigational RSV vaccine or RSV monoclonal antibody;
  7. Documented history of atrial fibrillation;
  8. History of severe allergic reactions requiring medical intervention [e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, or local allergic necrotic reaction (Arthus reaction)]; history of allergy to any component of the investigational vaccine; or history of other severe adverse reactions to vaccination;
  9. Physician-diagnosed abnormal coagulation function (e.g., coagulation factor deficiency, coagulation disease, or platelet abnormalities) or coagulation disorder that may contraindicate intramuscular injection;
  10. Anatomic or functional asplenia, or asplenia/splenectomy resulting from any condition;
  11. Current diagnosed neurologic or psychiatric disorder (including dementia, schizophrenia, or bipolar disorder), previous diagnosis of epilepsy or seizures (excluding febrile seizures in childhood), or other neurologic disease considered unsuitable for trial participation by the investigator;
  12. Diagnosed congenital or acquired immunodeficiency disease, such as human immunodeficiency virus infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, or another immune disease that may affect the trial assessment in the investigator's judgment;
  13. Long-term use (continuous use for 2 weeks or more) of immunosuppressants or other immunomodulatory medication within 6 months before enrollment or planned within 30 days after vaccination, such as long-term systemic corticosteroid therapy (continuous use for 2 weeks or more at a dose of at least 2 mg/kg/day or at least 20 mg/day of prednisone or equivalent). Topical medication (e.g., ointments, eye drops, inhalants, or nasal sprays) is permitted provided the labeled recommended dose is not exceeded;
  14. Known serious congenital malformation; developmental disorder or clinically diagnosed serious chronic disease (e.g., Down syndrome, diabetes with complications, sickle cell anemia, or neurologic disease);
  15. History of immune-mediated demyelinating disease, including but not limited to multiple sclerosis, neuromyelitis optica, acute disseminated encephalomyelitis, transverse myelitis, or Guillain-Barre syndrome;
  16. Known or suspected serious disease considered by the investigator to affect vaccination, including serious respiratory, digestive, endocrine, immune, cardiovascular, hepatic or renal disease, malignancy, or serious skin disease;
  17. Pregnant or breastfeeding women, or women planning to conceive within 6 months after vaccination;
  18. Receipt of blood products, including whole blood, plasma, gamma globulin, or immunoglobulin, within 3 months before vaccination, or plans to receive such treatment during the trial;
  19. Receipt of a live attenuated vaccine within 28 days before or planned within 28 days after investigational vaccine administration, or receipt of any non-live vaccine within 14 days before or planned within 14 days after investigational vaccine administration;
  20. Participation in another clinical trial within 6 months before the screening visit, or plans to participate in another clinical trial during this trial;
  21. Plans to move before the end of the trial or to be away from the local area for an extended period during scheduled trial visits;
  22. Any condition that, in the investigator's judgment, may affect the trial assessment.
04

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Low-Dose Antigen Cohort in subjects aged 18-59 years

    Subjects aged 18-59 years will receive single dose of Recombinant RSV Vaccine (CHO Cell), by IM injection into the deltoid muscle of the upper arm.

    Biological: Recombinant RSV Vaccine (CHO Cell)

  • Experimental
    High-Dose Antigen Cohort in subjects aged 18-59 years

    Subjects aged 18-59 years will receive double dose of Recombinant RSV Vaccine (CHO Cell), by IM injection into the deltoid muscle of the upper arm.

    Biological: Recombinant RSV Vaccine (CHO Cell)

  • Experimental
    Adjuvant Cohort in subjects aged 18-59 years

    Subjects aged 18-59 years will receive single dose of Adjuvant Suspension, by IM injection into the deltoid muscle of the upper arm.

    Biological: Adjuvant Suspension

  • Experimental
    Low-Dose Antigen + Adjuvant Cohort in subjects aged 18-59 years

    Subjects aged 18-59 years will receive single dose of Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension, by IM injection into the deltoid muscle of the upper arm.

    Biological: Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension

  • Placebo comparator
    Placebo group in subjects aged 18-59 years

    Subjects aged 18-59 years will receive single dose of placebo, by IM injection into the deltoid muscle of the upper arm.

    Biological: Saline solution

  • Experimental
    Low-Dose Antigen Cohort in subjects aged ≥60 years

    Subjects aged ≥60 years will receive single dose of Recombinant RSV Vaccine(CHO Cell), by IM injection into the deltoid muscle of the upper arm.

    Biological: Recombinant RSV Vaccine (CHO Cell)

  • Experimental
    High-Dose Antigen Cohort in subjects aged ≥60 years

    Subjects aged ≥60 years will receive single dose of Recombinant RSV Vaccine(CHO Cell), by IM injection into the deltoid muscle of the upper arm.

    Biological: Recombinant RSV Vaccine (CHO Cell)

  • Experimental
    Adjuvant Cohort in subjects aged ≥60 years

    Subjects aged ≥60 years will receive single dose of Adjuvant Suspension, by IM injection into the deltoid muscle of the upper arm.

    Biological: Adjuvant Suspension

  • Experimental
    Low-Dose Antigen + Adjuvant Cohort in subjects aged ≥60 years

    Subjects aged ≥60 years will receive single dose of Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension, by IM injection into the deltoid muscle of the upper arm.

    Biological: Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension

  • Placebo comparator
    Placebo group in subjects aged ≥60 years

    Subjects aged ≥60 years will receive single dose of placebo, by IM injection into the deltoid muscle of the upper arm.

    Biological: Saline solution

Interventions

  • BiologicalRecombinant RSV Vaccine (CHO Cell)

    0.4 mL per dose

  • BiologicalRecombinant RSV Vaccine (CHO Cell)

    0.8 mL per dose

  • BiologicalAdjuvant Suspension

    0.9 mL per dose

  • BiologicalRecombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension

    0.9 mL per dose

  • BiologicalSaline solution

    0.9 mL per dose

05

What researchers measure

Primary outcomes

  1. Incidence of immediate adverse events

    Incidence of all adverse events within 30 minutes after vaccination

    Time frame: Within 30 minutes after vaccination

  2. Incidence of solicited AEs

    Incidence of solicited (local and systemic) adverse events within 14 days after vaccination

    Time frame: Within 0-14 days after vaccination

  3. Incidence of unsolicited AEs

    Incidence of unsolicited adverse events within 30 days after vaccination

    Time frame: Within 30 days after vaccination

Secondary outcomes

  1. Incidence of clinically significant abnormalities in clinical laboratory tests

    Incidence of clinically significant abnormal laboratory test results on Day 4 after vaccination

    Time frame: 4 days after vaccination

  2. Incidence of clinically significant abnormal findings on 12-lead electrocardiograms

    Incidence of clinically significant abnormal findings on 12-lead electrocardiograms on Days 4, 14, and 30 after vaccination

    Time frame: 4 days, 14 days, 30 days after vaccination

  3. Occurrence of serious adverse events (SAEs)

    Occurrence of serious adverse events (SAEs) within 24 months after vaccination

    Time frame: Within 24 months after vaccination

  4. Occurrence of adverse events of special interest (AESIs)

    Occurrence of adverse events of special interest (AESIs) within 12 months after vaccination

    Time frame: Within 12 months after vaccination

  5. GMT of Neutralizing Antibody against RSV serotype A and B

    Measured by plaque reduction neutralization test (PRNT)

    Time frame: 30 days after vaccination

  6. GMFR of Neutralizing Antibody against RSV serotype A and B

    Measured by plaque reduction neutralization test (PRNT)

    Time frame: 30 days after vaccination

  7. SCR of Neutralizing Antibody against RSV serotype A and B

    Measured by plaque reduction neutralization test (PRNT)

    Time frame: 30 days after vaccination

  8. GMC of pre-F protein-binding antibodies

    Measured by enzyme-linked immunosorbent assay(ELISA)

    Time frame: 30 days after vaccination

  9. GMFR of pre-F protein-binding antibodies

    Measured by enzyme-linked immunosorbent assay(ELISA)

    Time frame: 30 days after vaccination

  10. SCR of pre-F protein-binding antibodies

    Measured by enzyme-linked immunosorbent assay(ELISA)

    Time frame: 30 days after vaccination

  11. GMT of Neutralizing Antibody against RSV serotype A and B

    Measured by plaque reduction neutralization test (PRNT)

    Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination

  12. GMFR of Neutralizing Antibody against RSV serotype A and B

    Measured by plaque reduction neutralization test (PRNT)

    Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination

  13. SCR of Neutralizing Antibody against RSV serotype A and B

    Measured by plaque reduction neutralization test (PRNT)

    Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination

  14. GMC of pre-F protein-binding antibodies

    Measured by enzyme-linked immunosorbent assay(ELISA)

    Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination

  15. GMFR of pre-F protein-binding antibodies

    Measured by enzyme-linked immunosorbent assay(ELISA)

    Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination

  16. SCR of pre-F protein-binding antibodies

    Measured by enzyme-linked immunosorbent assay(ELISA)

    Time frame: 14 days, 3 months, 6 months,12 months, 18 months and 24 months after vaccination

  17. The frequencies of antigen-specific T cells secreting IL-2 and IFN-γ

    Measured by ELISpot assay

    Time frame: 14 days, 30 days after vaccination

  18. The frequencies of antigen-specific CD4+ and CD8+ T cells expressing IL-2 and IFN-γ

    Measured by ICS assay

    Time frame: 14 days, 30 days after vaccination.

06

Study locations

1 site
  • Yixing People's Hospital
    Yixing, Jiangsu 214200, China
    • Hongxing Pan, Master · Contact · panhongxing@126.com · +86-18118996996
    • Hongxing Pan, Master · Principal investigator
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07807449
Lead sponsor
Yikang Biotech (Suzhou) Co., Ltd.
Collaborators
Jiangsu Province Centers for Disease Control and Prevention
Responsible party
Sponsor
First posted
Sep 8, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Jan 22, 2027 (estimated)
Completion
Jan 22, 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Xuqin Yang, Master
Contact
yangxuqin@ykangbio.com
+86-18600534482

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion